Home >> Research Area >>MAPK Signaling>>Raf>> Vemurafenib (PLX4032, RG7204)

Vemurafenib (PLX4032, RG7204)

BRAF kinase inhibitor CAS# 918504-65-1

Vemurafenib (PLX4032, RG7204)

Catalog No. BCC1269----Order now to get a substantial discount!

Product Name & Size Price Stock
Vemurafenib (PLX4032, RG7204): 5mg $35 In Stock
Vemurafenib (PLX4032, RG7204): 10mg Please Inquire In Stock
Vemurafenib (PLX4032, RG7204): 20mg Please Inquire Please Inquire
Vemurafenib (PLX4032, RG7204): 50mg Please Inquire Please Inquire
Vemurafenib (PLX4032, RG7204): 100mg Please Inquire Please Inquire
Vemurafenib (PLX4032, RG7204): 200mg Please Inquire Please Inquire
Vemurafenib (PLX4032, RG7204): 500mg Please Inquire Please Inquire
Vemurafenib (PLX4032, RG7204): 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Vemurafenib (PLX4032, RG7204)

Number of papers citing our products

Chemical structure

Vemurafenib (PLX4032, RG7204)

3D structure

Chemical Properties of Vemurafenib (PLX4032, RG7204)

Cas No. 918504-65-1 SDF Download SDF
PubChem ID 42611257 Appearance Powder
Formula C23H18ClF2N3O3S M.Wt 489.93
Type of Compound N/A Storage Desiccate at -20°C
Synonyms RG7204; R7204; RO5185426; PLX4032
Solubility DMSO : ≥ 100 mg/mL (204.11 mM)
H2O : < 0.1 mg/mL (insoluble)
*"≥" means soluble, but saturation unknown.
Chemical Name N-[3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl]propane-1-sulfonamide
SMILES CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=NC=C(C=C23)C4=CC=C(C=C4)Cl)F
Standard InChIKey GPXBXXGIAQBQNI-UHFFFAOYSA-N
Standard InChI InChI=1S/C23H18ClF2N3O3S/c1-2-9-33(31,32)29-19-8-7-18(25)20(21(19)26)22(30)17-12-28-23-16(17)10-14(11-27-23)13-3-5-15(24)6-4-13/h3-8,10-12,29H,2,9H2,1H3,(H,27,28)
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Vemurafenib (PLX4032, RG7204)

DescriptionVemurafenib (PLX4032, RG7204) is a novel and potent inhibitor of B-RafV600E with IC50 of 31 nM.
TargetsB-RafV600EC-RafMAP4K5 (KHS1)SRMSACK1FGR
IC5031 nM48 nM51 nM18 nM19 nM63 nM

Protocol

Cell experiment:

Cell lines

MALME-3M melanoma cell lines

Preparation method

The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.

Reacting condition

24 h; 10 μM

Applications

In melanoma cell lines, RG7204 was a potent inhibitor of proliferation in those expressing BRAFV600E but not BRAFWT. RG7204 also potently inhibited proliferation of melanoma cell lines expressing other codon 600 BRAF mutations (V600D, V600 K, and V600R).

Animal experiment:

Animal models

Athymic nude mice

Dosage form

100 mg/kg bid; oral taken.

Application

In mice bearing Colo829 tumor xenografts, RG7204 at 100 mg/kg bid for 21 days showed greatly improved antitumor activity compared both with vehicle (P = 0.001) at the end of the study on day 38 after the tumor cell implant. There was complete tumor regression in all 10 mice treated with RG7204 by the end of the study. Survival in the mice treated with RG7204 was significantly better than in those treated with vehicle (P = 0.0008).

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1] Yang H, Higgins B, Kolinsky K, et al. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models[J]. Cancer research, 2010, 70(13): 5518-5527.

Vemurafenib (PLX4032, RG7204) Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Vemurafenib (PLX4032, RG7204) Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Vemurafenib (PLX4032, RG7204)

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.0411 mL 10.2055 mL 20.4111 mL 40.8222 mL 51.0277 mL
5 mM 0.4082 mL 2.0411 mL 4.0822 mL 8.1644 mL 10.2055 mL
10 mM 0.2041 mL 1.0206 mL 2.0411 mL 4.0822 mL 5.1028 mL
50 mM 0.0408 mL 0.2041 mL 0.4082 mL 0.8164 mL 1.0206 mL
100 mM 0.0204 mL 0.1021 mL 0.2041 mL 0.4082 mL 0.5103 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Research Update of Vemurafenib (PLX4032, RG7204)

1. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032). J Pharmacol Exp Ther. 2012 Jul;342(1):33-40. doi: 10.1124/jpet.112.192195. Epub 2012 Mar 27.
Abstract
Vemurafenib is a BRAF inhibitor that has been approved by FDA for the treatment of metastatic melanoma patients with a BRAF(V600E) mutation. Active efflux by P-gp and BCRP significantly restricted the brain distribution of vemurafenib at the blood-brain barrier, where active efflux by P-gp and BCRP restricted intracellular accumulation of vemurafenib and altered bidirectional net flux of vemurafenib.
2. Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor. Future Oncol. 2012 May;8(5):509-23. doi: 10.2217/fon.12.31.
Abstract
Vemurafenib is a mutated BRAF kinase inhibitor that showed response rates of >50% in metastatic melanoma patients with BRAF mutation. In a Phase III study, the treatment of vemurafenib in previously untreated patients led to over survival of 84%, response rates of 48% and prolonged progression-free survival with largely reduced risk of death and disease progression.
4. Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations. J Transl Med. 2011 May 24;9:76. doi: 10.1186/1479-5876-9-76.
Abstract
The combined MAPK oncogene inhibition and metabolic modulation of AMPK is an effective treatment of melanoma cells due to a molecular linkage between the MAPK and the LKB1-AMPK pathways.
5. Stat3-targeted therapies overcome the acquired resistance to vemurafenib in melanomas. J Invest Dermatol. 2013 Aug;133(8):2041-9. doi: 10.1038/jid.2013.32. Epub 2013 Jan 23.
Abstract
Although the treatment of vemurafenib, a Braf inhibitor, in melanoma patients with Braf(V600E) mutations resulted in dramatic improvement with decreased risk of death and tumor progression, melanoma cells rapidly acquire vemurafenib resistance, which can be overcome by targeting Stat3-PAX3 signaling pathway.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Vemurafenib (PLX4032, RG7204)

Vemurafenib is an inhibitor of BRAF kinase. It inhibits BRAFV600E and also has inhibitory activity in vitro against several other kinds of kinases, including CRAF, ARAF and wild-type BRAF. Vemurafenib is a competitive small-molecule serine–threonine kinase inhibitor that functions by binding to the ATP-binding domain of mutant BRAF. Vemurafenib can also give rise to activation of downstream MEK by normal RAF homo- and heterodimers in non-BRAF mutated cells, which has been shown to be caused by transactivation of the nondrug-bound partner in BRAF to CRAF heterodimers and CRAF to CRAF homodimers.

Reference

Keith. T Flaherty, Uma Yasothan and Peter Kirkpatrick. Vemurafenib. Nature Reviews Drug Discovery. 2011; 10: 811 – 812.

Jason J. Luke, F. Stephen Hodi. Vemurafenib and BRAF Inhibition: A New Class of Treatment for Metastatic Melanoma. Clinical Cancer Research. 2012; 18: 9 – 14.

Featured Products
New Products
 

References on Vemurafenib (PLX4032, RG7204)

Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations.[Pubmed:21609436]

J Transl Med. 2011 May 24;9:76.

BACKGROUND: A molecular linkage between the MAPK and the LKB1-AMPK energy sensor pathways suggests that combined MAPK oncogene inhibition and metabolic modulation of AMPK would be more effective than either manipulation alone in melanoma cell lines. MATERIALS AND METHODS: The combination of the BRAF inhibitor vemurafenib (formerly PLX4032) and metformin were tested against a panel of human melanoma cell lines with defined BRAF and NRAS mutations for effects on viability, cell cycle and apoptosis. Signaling molecules in the MAPK, PI3K-AKT and LKB1-AMPK pathways were studied by Western blot. RESULTS: Single agent metformin inhibited proliferation in 12 out of 19 cell lines irrespective of the BRAF mutation status, but in one NRASQ61K mutant cell line it powerfully stimulated cell growth. Synergistic anti-proliferative effects of the combination of metformin with vemurafenib were observed in 6 out of 11 BRAFV600E mutants, including highly synergistic effects in two BRAFV600E mutant melanoma cell lines. Antagonistic effects were noted in some cell lines, in particular in BRAFV600E mutant cell lines resistant to single agent vemurafenib. Seven out of 8 BRAF wild type cell lines showed marginally synergistic anti-proliferative effects with the combination, and one cell line had highly antagonistic effects with the combination. The differential effects were not dependent on the sensitivity to each drug alone, effects on cell cycle or signaling pathways. CONCLUSIONS: The combination of vemurafenib and metformin tended to have stronger anti-proliferative effects on BRAFV600E mutant cell lines. However, determinants of vemurafenib and metformin synergism or antagonism need to be understood with greater detail before any potential clinical utility of this combination.

Description

Vemurafenib (PLX4032; RG7204; RO5185426) is a first-in-class, selective, potent inhibitor of B-RAF kinase, with IC50s of 31 and 48 nM for RAFV600E and c-RAF-1, respectively. Vemurafenib induces cell autophagy.

Keywords:

Vemurafenib (PLX4032, RG7204),918504-65-1,RG7204; R7204; RO5185426; PLX4032,Natural Products,Raf, buy Vemurafenib (PLX4032, RG7204) , Vemurafenib (PLX4032, RG7204) supplier , purchase Vemurafenib (PLX4032, RG7204) , Vemurafenib (PLX4032, RG7204) cost , Vemurafenib (PLX4032, RG7204) manufacturer , order Vemurafenib (PLX4032, RG7204) , high purity Vemurafenib (PLX4032, RG7204)

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: